Literature DB >> 2155728

Therapy of a fatal murine cytomegalovirus infection with thymic humoral factor (THF-gamma 2) treated immune spleen cells.

B Rager-Zisman1, F Zuckerman, D Benharroch, M Pecht, Y Burstein, N Trainin.   

Abstract

Infection of mice with murine cytomegalovirus (CMV) presents a model for the study of the role of the immune system in the pathogenesis of human CMV. We performed adoptive transfer experiments to evaluate the prospects for enhancing the anti-viral potential of murine CMV immune spleen cells by THF-gamma 2. Adult BALB/c mice resistant to murine CMV become highly susceptible following immunosuppression by cyclophosphamide. Recipient mice were injected with murine CMV and cyclophosphamide concomitantly, and 24 h later adoptive transfers of syngeneic immune spleen cells were performed. We showed that passive transfers of murine CMV immune spleen cells prevented the development of a fatal disease in 38% of the recipient mice. Daily injections of murine CMV immune donor mice with THF-gamma 2 enhanced considerably (93%) the therapeutic potential of virus-specific immune cells. These experiments provide direct evidence for the antiviral capacity of THF-gamma 2 through its immunomodulatory effect on immune T cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155728      PMCID: PMC1534746          DOI: 10.1111/j.1365-2249.1990.tb05186.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  Cytotoxic T lymphocyte response to murine cytomegalovirus infection.

Authors:  G V Quinnan; J E Manischewitz; F A Ennis
Journal:  Nature       Date:  1978-06-15       Impact factor: 49.962

Review 2.  Congenital cytomegalovirus disease: a NOW problem.

Authors:  M D Yow
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

3.  A useful quantitative semimicromethod for viral plaque assay.

Authors:  B Rager-Zisman; T C Merigan
Journal:  Proc Soc Exp Biol Med       Date:  1973-04

Review 4.  Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience.

Authors:  J D Meyers; N Flournoy; E D Thomas
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec

5.  Involvement of natural killer cells in the pathogenesis of murine cytomegalovirus interstitial pneumonitis and the immune response to infection.

Authors:  G V Quinnan; J F Manischewitz; N Kirmani
Journal:  J Gen Virol       Date:  1982-01       Impact factor: 3.891

6.  Genetic influences on the augmentation of natural killer (NK) cells during murine cytomegalovirus infection: correlation with patterns of resistance.

Authors:  G J Bancroft; G R Shellam; J E Chalmer
Journal:  J Immunol       Date:  1981-03       Impact factor: 5.422

7.  Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant.

Authors:  J D Meyers; N Flournoy; E D Thomas
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

8.  Role of T lymphocytes in recovery from murine cytomegalovirus infection.

Authors:  S E Starr; A C Allison
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

9.  The pathogenesis of pneumonitis due to murine cytomegalovirus.

Authors:  J D Shanley; E L Pesanti; K M Nugent
Journal:  J Infect Dis       Date:  1982-09       Impact factor: 5.226

10.  Modification by adoptive humoral immunity of murine cytomegalovirus infection.

Authors:  J D Shanley; M C Jordan; J G Stevens
Journal:  J Infect Dis       Date:  1981-02       Impact factor: 5.226

View more
  2 in total

1.  A little cooperation helps murine cytomegalovirus (MCMV) go a long way: MCMV co-infection rescues a chemokine salivary gland defect.

Authors:  Pranay Dogra; Mindy Miller-Kittrell; Elisabeth Pitt; Joseph W Jackson; Tom Masi; Courtney Copeland; Shuen Wu; William E Miller; Tim Sparer
Journal:  J Gen Virol       Date:  2016-09-13       Impact factor: 3.891

2.  Combined effect of fluconazole and thymosin alpha 1 on systemic candidiasis in mice immunosuppressed by morphine treatments.

Authors:  P di Francesco; R Gaziano; I A Casalinuovo; L Belogi; A T Palamara; C Favalli; E Garaci
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.